Every biopharma patent filing is a confession. It tells you what a company believes is worth protecting, who did the […]

Every major drug company has a clock running in its boardroom. When a blockbuster patent expires, billions in annual revenue

In 2002, AbbVie launched adalimumab—a monoclonal antibody for rheumatoid arthritis sold under the brand name Humira—at a price of roughly

Every pharmaceutical acquisition has a number at its core that almost nobody states plainly: the price you are paying for

The Market Nobody Reads Correctly Russia’s pharmaceutical market generated 2.85 trillion roubles in 2024, roughly $30.9 billion at prevailing exchange

Every drug that reaches Phase III clinical trials carries two price tags: the cost of making it and the cost

Every year, generic drug manufacturers pay hundreds of millions of dollars in settlements and delayed-entry agreements that, in hindsight, were

By the time a patent cliff arrives, most pharmaceutical companies have already lost the war. The moment generic manufacturers file

Russia is a $9.2 billion pharmaceutical market where the rulebook on intellectual property is being rewritten in real time. [1]